Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,530 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Evaluation Clear all
Completed Not applicable Interventional

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

NCT00002354
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 6:27 PM EDT
Withdrawn Not applicable Interventional

Telepharmacy Robotic Medicine Delivery Unit "TRMDU" Assessment

NCT01007006
View directory record Official record
Conditions
Traumatic Brain Injury, Posttraumatic Stress Disorders, Trauma, Combat Disorders, Pain
Interventions
TMRDU
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Camp Pendleton, California • Tampa, Florida • Fort Knox, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

NCT01306643
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
Interventions
Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 2 Interventional

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

NCT00034021
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions
Ginkgo Biloba, Sex Therapy (genital focus)
Drug · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 6, 2026, 6:27 PM EDT
Terminated Phase 1 Interventional Results available

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

NCT02551055
View directory record Official record
Conditions
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
Interventions
MLN1117, TAK-659, Alisertib, Paclitaxel, Docetaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Lake Success, New York • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

NCT00002193
View directory record Official record
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
6 Months to 18 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Mindfulness and Yoga for Pain With Interstitial Cystitis Evaluation

NCT04820855
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Treatment, Usual Cares
Behavioral · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

NCT00002178
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Preoperative Skin Preparation Evaluation

NCT00636480
View directory record Official record
Conditions
Topical Antisepsis
Interventions
Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2008 · Synced Sep 6, 2026, 6:27 PM EDT
Not listed No phase listed Observational

Evaluation of PatientToc in Community Pharmacies

NCT05235620
View directory record Official record
Conditions
Medication Adherence
Interventions
PatientToc use in pharmacies
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 2 Interventional

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

NCT02252835
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Arhalofenate, Febuxostat, Colchicine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

NCT00534378
View directory record Official record
Conditions
Seizures
Interventions
Midazolam
Drug
Lead sponsor
U.S. Army Office of the Surgeon General
Federal
Eligibility
18 Years to 54 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2007 · Synced Sep 6, 2026, 6:27 PM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Not applicable Interventional

More Individualized Care: Assessment and Recovery Through Engagement

NCT05122676
View directory record Official record
Conditions
Depression, Anxiety, Opioid-Related Disorders, Pain, Chronic
Interventions
More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia

NCT02228720
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Propel Nova Sinus Implant
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 6, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 6:27 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

NCT02475746
View directory record Official record
Conditions
Healthy
Interventions
PF-06372865, itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

NCT06190561
View directory record Official record
Conditions
Healthy
Interventions
PF-07940367
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 6, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

NCT07426120
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration, Phase III
Interventions
Total coumarin (TC) cream, Vehicle cream
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 6, 2026, 6:27 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

NCT00000897
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 6, 2026, 6:27 PM EDT